The recombinant inhibitor, according to Travis, worked perfectly. By manipulating just one residue in the protein, Guengerich says, they had created "a better protein than nature has produced, which is not susceptible to oxidation." For people who have only 10% of the normal amount of inhibitor, protecting the functional inhibitor they do have is essential.
The next step was to test the synthesized molecules' half-lives in rabbits. Travis brought natural and altered recombinant molecules with him to the University of Canterbury in Christchurch, New Zealand, during a 6-month sabbatical. He and his colleagues in Christchurch labeled the inhibitors using iodine-125 and then took aliquots at various times to see how much remained in the rabbit plasma. They found that the natural molecule had a half-life of 2.2 days, whereas the half-life of the recombinant molecule was under 7 h.
Because yeast do not glycosylate or label recombinant molecules in the normal way, the investigators found that this protein is turned over too rapidly to be of therapeutic use. "To infuse it into the blood plasma would not work at all because the half-life is so short," says Travis. "Very little of it would get to its target before it was removed from circulation."
Because of the glycosylation problem, Chiron abandoned the project. As an alternative, some drug companies currently purify the inhibitor from plasma and administer it to people with advanced emphysema; the purified inhibitor has been shown to improve symptoms and prolong lives. But Olson notes that the plasma treatment currently available is very expensive, approximately $100,000 per year.
Travis is hopeful the valine-modified inhibitor might be used in treatment one day. He believes it could be administered as an aerosol, which would deliver it directly to the lungs where the half-life should not matter. Recombinant proteins such as the one Travis helped to develop could provide an alternative to plasma derivatives. Olson says, "I think it's potentially a way of reducing the price of this therapy in the future." DOI 10.1074/jbc.O117.000001
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